Date: 2013-02-25
Type of information: Grant
Company: Biocartis (Belgium)
Investors: Flemish agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: € 1.9 million
Funding type: grant
Planned used: Biocartis will use this IWT-subsidy (from the Flemish government) to develop new diagnostic cancer tests that will facilitate more targeted treatment and improve survival rates for patients.
Others: Biocartis is a molecular diagnostics company that develops clinically relevant tests and innovative, easy-to-use platforms to be employed, amongst other indications, in the fight against cancer. During the two-year project a number of new cancer tests will be developed to be used on the fully automated Biocartis systems. The tests will detect known, validated oncogenes (cancer-causing mutations in the genome) and allow for more targeted treatment of certain cancers. The project will focus on skin, colon and lung cancer. Biocartis will also develop tests that permit the simultaneous detection of dozens of parameters for use with its recently launched multiplex detection platform aimed at the research market.
Therapeutic area:
